MEDIA

Speaking, Writing, and Media

16 Pitfalls to Avoid in Building a Computational Therapeutics Company

Forbes 30 under 30 in Venture Capital

UCSF Health Awards 2021, Judge

Emerging Trends, Evolving Landscapes, & Effective Collaboration, AI Innovation Circle: Pharmaceuticals and Healthcare 2021

Investing Trends in Precision Medicine, MedCity INVEST Precision Medicine 2020

Shifting Risk Mindsets, From Tech to Bio, a16z Podcast

Shifting Risk Mindsets, From Tech to Bio, a16z Video

 

Taking the Pulse on Bio, a16z Podcast

Scaling Healthcare, a16z Summit 2017 with Sean Duffy, CEO Omada Health and Rajeev Singh, CEO Accolade

On Recent Consolidation in the Healthcare Industry, a16z Podcast

What to Make of Consolidation in Healthcare?, a16z Video

The Future of Healthcare Investment, Harvard Business School Healthcare Initiative 2015

Yale Baim Scholarship

Selected Peer Reviewed Publications

Shifting Risk Mindsets, from Tech to Bio
26:37

Shifting Risk Mindsets, from Tech to Bio

What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how does it differ from traditional tech companies? In this hallway-style conversation, a16z bio team partners -- including general partners Jorge Conde and Vijay Pande, with Jeff Low -- discuss the mindset shifts involved with building bio (and especially therapeutics) companies. They cover everything from different paths to market and different partnerships (including pharma), to different timelines and milestones for validating the product and business itself. And finally, how do we get to common language that bridges the worlds of tech and bio? *** The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Consolidation in Healthcare: What to Make of It?
07:43

Consolidation in Healthcare: What to Make of It?

Healthcare headlines have been all around consolidation in the industry: Walmart and Humana; Aetna and CVS; Amazon, JP Morgan, and Berkshire Hathaway. In this hallway-style conversation, a16z bio team partners -- Jorge Conde and Vijay Pande, with Jeffrey Low -- discuss what's going on as we see more vertical integration across the healthcare value chain. Will it decrease costs? How will these different "consortiums" drive value to patients, at a local level? And finally, what opportunities open up as a result of all this? *** The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
PNAS_inra_image.png

Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection

Kerry A. Millington, Sarah M. Fortune, Jeffrey Low, Alejandra Garces, Suzanne M. Hingley-Wilson, Melissa Wickremasinghe, Onn M. Kon, and Ajit Lalvani

Annals of internal medicine.png

A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic

Harlan M. Krumholz, MD, SM, Joseph S. Ross, MD, MHS, Cary P. Gross, MD, Ezekiel J. Emanuel, MD, PhD, Beth Hodshon, JD, MPH, RN, Jessica D. Ritchie, MPH, Jeffrey B. Low, AB, Richard Lehman, MD

Systematic Reviews.png

Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project

Jeffrey Low, Joseph S. Ross, Jessica D. Ritchie, Cary P. Gross, Richard Lehman, Haiqun Lin, Rongwei Fu, Lesley A. Stewart & Harlan M. Krumholz

Spine moving foward.jpeg

Moving Forward From rhBMP-2: Open Science and Data Sharing

Jeffrey B Low, Joseph S Ross, Harlan M Krumholz

yale%2520smaller_edited_edited.png

Operationalizing Value-Based Healthcare Strategies: Data Sharing & Cost Measurement In Orthopaedics

Jeffrey Low

Thesis advised by Gary Friedlaender and Kevin Bozic

business of neurosurgery.jpg

Disruptive Innovation: The Role of Hospitals, Integration, and the Value-Added Process

Jeffrey Low, Richard Menger, Gregory Mundis Jr.

spine complications.jpeg

Complications Associated With the Use of the Recombinant Human Bone Morphogenetic Proteins for Posterior Interbody Fusions of the Lumbar Spine

Chrastil, Jesse, MD; Low, Jeffrey B., BA; Whang, Peter G., MD, FACS; Patel, Alpesh A., MD, FACS

Spine moving foward.jpeg

ProDisc-L Total Disc Replacement: A Comparison of 1-Level Versus 2-Level Arthroplasty Patients With a Minimum 2-Year Follow-up

Hannibal, Matthew, MD; Thomas, Derek J., MD; Low, Jeffrey; Hsu, Ken Y., MD; Zucherman, James, MD